Xilio Therapeutics appoints Caroline Hensley as chief legal officer to enhance legal support for tumor-activated immuno-oncology therapies.
Quiver AI Summary
Xilio Therapeutics, Inc. has appointed Caroline (Holda) Hensley as its new chief legal officer. With extensive experience in the life sciences sector, Hensley previously held the position of senior vice president, assistant general counsel, and chief compliance officer at Seres Therapeutics, where she managed various legal and compliance matters. She holds a B.A. in economics from the University of Texas at Austin and a J.D. from Boston University School of Law. Xilio Therapeutics focuses on developing tumor-activated immuno-oncology therapies aimed at improving cancer treatment outcomes while minimizing systemic side effects. Hensley expressed her enthusiasm for joining Xilio at a crucial time in the company's development.
Potential Positives
- Appointment of Caroline Hensley as chief legal officer brings significant legal and compliance expertise, enhancing the company’s leadership team.
- Ms. Hensley's background in biotechnology and experience with capital markets and regulatory compliance can support Xilio Therapeutics' growth and development of its immuno-oncology therapies.
- The press release highlights Xilio’s focus on advancing a promising pipeline of tumor-activated therapies, indicating ongoing commitment to innovation in cancer treatment.
Potential Negatives
- The appointment of a new chief legal officer may indicate potential existing legal or compliance challenges within the company that necessitated a strengthened leadership position in this area.
- The mention of the company being at a "pivotal moment" could suggest that Xilio Therapeutics is facing significant pressures or uncertainties in its development pipeline or market position.
- The focus on compliance and regulatory oversight in Ms. Hensley's previous role might imply that Xilio is prioritizing risk management due to past or present regulatory concerns.
FAQ
Who is the newly appointed chief legal officer of Xilio Therapeutics?
Caroline (Holda) Hensley has been appointed as the chief legal officer of Xilio Therapeutics.
What is the role of Caroline Hensley at Xilio Therapeutics?
Caroline Hensley will oversee corporate legal and compliance matters at Xilio Therapeutics.
What experience does Caroline Hensley bring to Xilio Therapeutics?
Caroline Hensley has extensive experience in advising public life science companies on legal and compliance issues.
What is the focus of Xilio Therapeutics?
Xilio Therapeutics focuses on developing tumor-activated immuno-oncology therapies to improve cancer treatment outcomes.
Where can I find more information about Xilio Therapeutics?
More information about Xilio Therapeutics can be found on their official website at www.xiliotx.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$XLO Hedge Fund Activity
We have seen 14 institutional investors add shares of $XLO stock to their portfolio, and 14 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC removed 992,912 shares (-100.0%) from their portfolio in Q2 2024
- BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC added 781,367 shares (+20.6%) to their portfolio in Q3 2024
- MORGAN STANLEY added 409,362 shares (+36.8%) to their portfolio in Q3 2024
- GEODE CAPITAL MANAGEMENT, LLC added 155,337 shares (+85.0%) to their portfolio in Q3 2024
- ENGINEERS GATE MANAGER LP added 32,752 shares (+inf%) to their portfolio in Q3 2024
- TWO SIGMA SECURITIES, LLC added 31,174 shares (+234.9%) to their portfolio in Q3 2024
- PFG INVESTMENTS, LLC removed 30,000 shares (-100.0%) from their portfolio in Q2 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Caroline (Holda) Hensley as chief legal officer.
“Caroline is an accomplished lawyer and biotechnology executive who brings a wealth of experience advising public life science companies across all stages of development and commercialization,” said René Russo, Pharm.D., president and chief executive officer of Xilio. “Her expertise and strategic insights make her a tremendous addition to our executive team, and we are excited to have her onboard.”
Ms. Hensley most recently served as senior vice president, assistant general counsel and chief compliance officer at Seres Therapeutics, Inc., where she oversaw all corporate legal and compliance matters, including capital markets and licensing transactions, clinical development and commercial launch activities, partnership/collaboration management, and FDA and healthcare regulatory compliance matters. Previously, Ms. Hensley was a corporate associate in the Boston office of Latham & Watkins, where she represented public and private companies in biotechnology and other industries across a range of capital markets and strategic transactions throughout their lifecycle. She received her B.A. in economics from the University of Texas at Austin and her J.D. from the Boston University School of Law.
“I am thrilled to join the Xilio team at this pivotal moment in the company's growth and look forward to helping to advance Xilio’s promising pipeline of novel, tumor-activated immuno-oncology therapies,” said Ms. Hensley.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecifics and immune cell engagers. Learn more by visiting
www.xiliotx.com
and follow us on LinkedIn (
Xilio Therapeutics, Inc
.).
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Investor and Media Contact
Scott Young
Vice President, Investor Relations and Corporate Communications
investors@xiliotx.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
